

Christian Recher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3991304/publications.pdf>

Version: 2024-02-01

151
papers

13,239
citations

23567

58
h-index

24258

110
g-index

158
all docs

158
docs citations

158
times ranked

14193
citing authors

#	ARTICLE	IF	CITATIONS
1	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. <i>Blood</i> , 2015, 126, 291-299.	1.4	982
2	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	27.0	796
3	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. <i>Cancer Discovery</i> , 2017, 7, 716-735.	9.4	582
4	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology</i> , 2014, 15, 986-996.	10.7	549
5	High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. <i>New England Journal of Medicine</i> , 2007, 357, 1083-1093.	27.0	473
6	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. <i>Journal of Clinical Oncology</i> , 2011, 29, 3322-3327.	1.6	421
7	Improved survival in cancer patients requiring mechanical ventilatory support: Impact of noninvasive mechanical ventilatory support. <i>Critical Care Medicine</i> , 2001, 29, 519-525.	0.9	393
8	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e186-e195.	4.6	359
9	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. <i>Blood</i> , 2011, 117, 403-411.	1.4	348
10	Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R β -deficient mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 384-395.	8.2	336
11	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2213-2223.	1.4	313
12	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. <i>Lancet</i> , 2011, 378, 1858-1867.	13.7	311
13	Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. <i>Blood</i> , 2015, 126, 1346-1356.	1.4	303
14	Antileukemic activity of rapamycin in acute myeloid leukemia. <i>Blood</i> , 2005, 105, 2527-2534.	1.4	280
15	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. <i>Blood</i> , 2010, 115, 1690-1696.	1.4	232
16	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. <i>Blood</i> , 2013, 121, 822-829.	1.4	189
17	Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2022, 386, 1519-1531.	27.0	186
18	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	1.4	183

#	ARTICLE	IF	CITATIONS
19	Eprenetapopt Plus Azacitidine in <i>TP53</i> -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myéloblastoses (GFM). <i>Journal of Clinical Oncology</i> , 2021, 39, 1575-1583.	1.6	169
20	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2492-2499.	1.6	165
21	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aigues et Maladies du Sang (GOELAMS) study. <i>Haematologica</i> , 2011, 96, 1792-1798.	3.5	164
22	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 2402-2411.	13.7	157
23	Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. <i>Cancer</i> , 2015, 121, 234-242.	4.1	144
24	Expression of Focal Adhesion Kinase in Acute Myeloid Leukemia Is Associated with Enhanced Blast Migration, Increased Cellularity, and Poor Prognosis. <i>Cancer Research</i> , 2004, 64, 3191-3197.	0.9	140
25	Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 111, 196-203.	2.5	138
26	A critical role for Lyn in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 2269-2279.	1.4	137
27	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 1025-1036.	10.7	129
28	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. <i>Journal of Clinical Oncology</i> , 2009, 27, 4747-4753.	1.6	123
29	Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. <i>Journal of Clinical Virology</i> , 2010, 49, 141-144.	3.1	120
30	Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. <i>Oncotarget</i> , 2010, 1, 34-42.	1.8	115
31	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. <i>Blood</i> , 2016, 127, 882-892.	1.4	108
32	High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. <i>Leukemia</i> , 2017, 31, 2326-2335.	7.2	106
33	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2618-2626.	1.4	100
34	Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. <i>Nature Communications</i> , 2020, 11, 4056.	12.8	96
35	Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. <i>American Journal of Hematology</i> , 2014, 89, 410-416.	4.1	91
36	mTOR, A New Therapeutic Target in Acute Myeloid Leukemia. <i>Cell Cycle</i> , 2005, 4, 1540-1549.	2.6	90

#	ARTICLE	IF	CITATIONS
37	Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en <i>Respiratoire et Oncologie Hématologique</i> . <i>British Journal of Haematology</i> , 2013, 162, 489-497.	2.5	90
38	The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. <i>Cell Reports</i> , 2014, 7, 1815-1823.	6.4	86
39	Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. <i>Journal of Clinical Oncology</i> , 2022, 40, 855-865.	1.6	86
40	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. <i>Nature Communications</i> , 2017, 8, 1903.	12.8	84
41	Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003.	1.6	79
42	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	1.6	77
43	Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study. <i>Blood</i> , 2011, 118, 79-79.	1.4	77
44	Prolonged hepatitis E in an immunocompromised patient. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1223-1224.	2.8	75
45	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 32532-32542.	1.8	75
46	CHK1 as a therapeutic target to bypass chemoresistance in AML. <i>Science Signaling</i> , 2016, 9, ra90.	3.6	73
47	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	5.2	72
48	Role of <i>ASXL1</i> and <i>TP53</i> mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. <i>Oncotarget</i> , 2015, 6, 8388-8396.	1.8	69
49	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016, 213, 483-497.	8.5	68
50	Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy. <i>Cancer Research</i> , 2009, 69, 8652-8661.	0.9	67
51	Incidence of 17p deletions and <i>TP53</i> mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1086-1092.	2.8	67
52	Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells. <i>Oncogene</i> , 2004, 23, 7507-7516.	5.9	63
53	Azacitidine for the treatment of relapsed and refractory AML in older patients. <i>Leukemia Research</i> , 2015, 39, 124-130.	0.8	63
54	Improved outcome for AML patients over the years 2000-2014. <i>Blood Cancer Journal</i> , 2017, 7, 635.	6.2	63

#	ARTICLE	IF	CITATIONS
55	APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des My�lodysplasies (GFM). <i>Blood</i> , 2019, 134, 677-677.	1.4	62
56	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. <i>Blood</i> , 2014, 124, 1312-1319.	1.4	61
57	Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy. <i>Haematologica</i> , 2014, 99, 474-480.	3.5	61
58	Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 7676-7684.	1.6	59
59	Efficacy of lenalidomide in <sc>POEMS</sc> syndrome: A retrospective study of 20 patients. <i>American Journal of Hematology</i> , 2013, 88, 207-212.	4.1	59
60	Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network. <i>American Journal of Hematology</i> , 2014, 89, E244-52.	4.1	59
61	Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. <i>BMC Cancer</i> , 2017, 17, 852.	2.6	57
62	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 131-142.	2.2	57
63	Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2012, 54, 152-155.	3.1	56
64	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <i>Blood Advances</i> , 2021, 5, 176-184.	5.2	56
65	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	56
66	Follow-up of patients with R/R <i>FLT3</i>-mutation��positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	1.4	55
67	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. <i>Blood</i> , 2013, 122, 738-748.	1.4	53
68	Antileukemic Activity of 2-Deoxy- <i>d</i> -Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with <i>FLT3-ITD</i> or <i>c-KIT</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2364-2373.	4.1	52
69	EV11 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 349-356.	2.8	51
70	Molecular Evidence of Patient-to-Patient Transmission of Hepatitis E Virus in a Hematology Ward. <i>Clinical Infectious Diseases</i> , 2009, 48, 373-374.	5.8	51
71	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2017, 31, 2493-2501.	2.2	51
72	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 1641-1646.	1.6	49

#	ARTICLE	IF	CITATIONS
73	Dexamethasone in hyperleukocytic acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 988-998.	3.5	49
74	Prognostic impact of <i>DDX41</i> germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. <i>Blood</i> , 2022, 140, 756-768.	1.4	48
75	Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia. <i>Cancer Research</i> , 2019, 79, 5191-5203.	0.9	45
76	Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. <i>Haematologica</i> , 2014, 99, 46-53.	3.5	44
77	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1204-1223.	13.2	42
78	Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. <i>Emerging Infectious Diseases</i> , 2015, 21, 1466-1469.	4.3	41
79	Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1544-1565.	9.4	39
80	Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. <i>Haematologica</i> , 2010, 95, 996-1003.	3.5	38
81	Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 387-393.	1.6	38
82	Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. <i>Nature Communications</i> , 2021, 12, 3084.	12.8	38
83	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 1223-1230.	1.6	37
84	Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS. <i>Journal of Clinical Oncology</i> , 2010, 28, 3028-3034.	1.6	36
85	Prognostic significance of concurrent gene mutations in intensively treated patients with <i>IDH</i> -mutated AML, an ALFA study. <i>Blood</i> , 2021, 137, 2827-2837.	1.4	36
86	Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. <i>Nature Communications</i> , 2021, 12, 422.	12.8	36
87	Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status. <i>Leukemia Research</i> , 2010, 34, 498-506.	0.8	35
88	Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. <i>Leukemia Research</i> , 2017, 61, 62-67.	0.8	33
89	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. <i>Blood</i> , 2021, 137, 524-532.	1.4	33
90	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in <i>NPM1</i> -mutated patients. <i>Haematologica</i> , 2017, 102, 1718-1726.	3.5	32

#	ARTICLE	IF	CITATIONS
91	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3203-3210.	1.6	32
92	Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey. <i>Haematologica</i> , 2018, 103, 2040-2048.	3.5	31
93	Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 79126-79136.	1.8	30
94	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. <i>Oncotarget</i> , 2011, 2, 850-861.	1.8	29
95	Clinical Implications of Inflammation in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 623952.	2.8	28
96	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e185-e187.	3.5	27
97	Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. <i>Oncogenesis</i> , 2019, 8, 39.	4.9	26
98	Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. <i>Leukemia Research</i> , 2015, 39, 818-821.	0.8	24
99	Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy. <i>BMC Cancer</i> , 2015, 15, 781.	2.6	23
100	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922.	7.2	23
101	Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy. <i>American Journal of Hematology</i> , 2016, 91, 193-198.	4.1	22
102	Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. <i>Blood</i> , 2019, 134, 14-14.	1.4	20
103	Comparison of 60 or 90 mg/m ² of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. <i>American Journal of Hematology</i> , 2015, 90, E29-30.	4.1	19
104	A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival. <i>BMC Cancer</i> , 2015, 15, 288.	2.6	16
105	Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients. <i>BMC Cancer</i> , 2019, 19, 883.	2.6	15
106	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1880-1886.	1.3	14
107	Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience. <i>Cancer Medicine</i> , 2019, 8, 3846-3854.	2.8	14
108	In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. <i>Blood Advances</i> , 2022, 6, 1804-1812.	5.2	14

#	ARTICLE	IF	CITATIONS
109	Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. <i>Blood Advances</i> , 2020, 4, 3840-3849.	5.2	13
110	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. <i>Cancers</i> , 2020, 12, 1725.	3.7	13
111	Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. <i>PLoS ONE</i> , 2020, 15, e0238795.	2.5	12
112	Early detection of <i>WT1</i> measurable residual disease identifies high-risk patients, independent of transplantation in AML. <i>Blood Advances</i> , 2021, 5, 5258-5268.	5.2	12
113	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1237-1252.	7.2	12
114	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	6.2	12
115	A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. <i>British Journal of Haematology</i> , 2022, 198, 535-544.	2.5	12
116	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. <i>Clinical Epigenetics</i> , 2019, 11, 141.	4.1	11
117	Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. <i>Leukemia Research</i> , 2019, 81, 82-87.	0.8	11
118	Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study. <i>Cancers</i> , 2020, 12, 773.	3.7	11
119	Dactinomycin in acute myeloid leukemia with NPM1 mutations. <i>European Journal of Haematology</i> , 2020, 105, 302-307.	2.2	10
120	Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. <i>British Journal of Haematology</i> , 2022, 196, 995-1006.	2.5	10
121	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. <i>Oncotarget</i> , 2016, 7, 85937-85947.	1.8	9
122	Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. <i>Cancers</i> , 2020, 12, 2044.	3.7	8
123	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. <i>Blood Advances</i> , 2020, 4, 5322-5335.	5.2	8
124	Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 2933.	3.7	7
125	CD34 ⁺ CD38 [~] CD123 ⁺ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. <i>Cancers</i> , 2020, 12, 1174.	3.7	7
126	Genomic landscape of hyperleukocytic acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 4.	6.2	7

#	ARTICLE	IF	CITATIONS
127	Impact of body surface area on patients' outcome in younger adults with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2017, 98, 443-449.	2.2	6
128	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. <i>Cancer Medicine</i> , 2021, 10, 6336-6343.	2.8	6
129	MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 875-887.	4.2	6
130	Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations. <i>Cancers</i> , 2021, 13, 5243.	3.7	6
131	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300.	7.2	5
132	Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML. <i>Blood</i> , 2019, 134, 1416-1416.	1.4	5
133	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	5
134	Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006 intermediate-risk trial. <i>European Journal of Haematology</i> , 2021, 107, 111-121.	2.2	4
135	A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	4
136	Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1289293.	0.7	3
137	Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies. <i>Leukemia and Lymphoma</i> , 2019, 60, 238-241.	1.3	3
138	More than ten percent of relapses occur after five years in AML patients with NPM1 mutation. <i>Leukemia and Lymphoma</i> , 2020, 61, 1226-1229.	1.3	3
139	The beginning of a new therapeutic era in acute myeloid leukemia. <i>EJHaem</i> , 2021, 2, 823-833.	1.0	3
140	Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study. <i>Leukemia and Lymphoma</i> , 2022, 63, 1398-1406.	1.3	3
141	DNA polymerase β gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status. <i>Haematologica</i> , 2018, 103, 1038-1046.	3.5	2
142	Outcome of relapsed/refractory AML patients with IDH1 ^{R132} mutations in real life before the era of IDH1 inhibitors. <i>Leukemia and Lymphoma</i> , 2020, 61, 473-476.	1.3	2
143	AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S179.	0.4	2
144	Large granular lymphocytosis during quizartinib therapy. <i>British Journal of Haematology</i> , 2020, 189, 7-7.	2.5	2

#	ARTICLE	IF	CITATIONS
145	Hematidrosis as a manifestation of COVID-19 containment-induced stress. <i>EJHaem</i> , 2021, 2, 25-25.	1.0	2
146	Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. <i>European Journal of Haematology</i> , 2021, 106, 859-867.	2.2	2
147	Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 180.	6.2	2
148	Nouvelles approches thérapeutiques dans les leucémies aiguës myéloïdes. <i>Revue Francophone Des Laboratoires</i> , 2015, 2015, 65-73.	0.0	0
149	A case of cup-like blasts associated with B-lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations. <i>EJHaem</i> , 2020, 1, 589-592.	1.0	0
150	Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients. <i>Hematologic Malignancies</i> , 2021, , 241-254.	0.2	0
151	Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. <i>Pharmaceutics</i> , 2022, 14, 792.	4.5	0